Abstract
Introduction: Ceruloplasmin is an enzyme that uses copper as a cofactor. It can be determined in the laboratory by determining its enzymatic activity, which considers only the active portion, or by measuring its protein concentration, which considers both the active and inactive portion. Ceruloplasmin is useful in diagnosing Wilson’s and Menkes’ diseases, in which it is found mainly as an inactive form due to low circulating copper. This means that methods that measure concentration can overestimate it and lose diagnostic sensitivity. Objective: To evaluate the correlation and concordance between an enzymatic method and an immunoturbidimetric method to measure Ceruloplasmin. Materials and methods: An analytical observational study was carried out to compare the enzymatic method of Henry et al. and the CERU® immunoturbidimetric method (Roche, Cobas c311) for the determination of Ceruloplasmin, using serum samples from pediatric patients, with medical request for this determination, in the period April 2018 - March 2021. The statistical analysis performed (IBM SPSS Statistics version 21) consisted of a correlation study (Pearson) and a concordance study (Bland Altman). Results: 51 samples were analyzed, obtaining r=0.916 in the Pearson correlation (p<0.0001) and a Bland Altman graph with positive bias. Conclusion: A good correlation was found, although the concordance analysis showed a positive bias. Since the agreement is good in the medical decision area, it is concluded that both methodologies can be interchangeable.
References
Cormenzana JC. Hemocromatosis, Alteraciones del metabolismo del cobre y déficit del cofactor de molibdeno. En: Sanjurjo P. Baldellou A. Diagnóstico y tratamiento de enfermedades metabólicas hereditarias. 3era Edición. Madrid: Ergon; 2010, p 1039-1052. DOI: 10.1157/13124906.
Zena Leah H. Ceruloplasmin. En: Kerkar N, Roberts EA. Clinical and Translational Perspectives on Wilson Disease. California: Academic Press; 2019. p 77-84. ISBN: 9780128105320.
Servin R, Bay L, Eiroa H, Avalo M, Braverman A, Zappa J, et al. Enfermedad de Menkes: Presentación de un caso y revisión bibliográfica. Arch. argent. Pediatr. 1991; 89 (6): 274-281. LILACS: lil-560320.
Yapur VM, Bustos MF, González AS, Negri GA. Ceruloplasmina: determinación de su actividad ferroxidasa. ABCLDL. Acta Bioquímica Clínica Latinoamericana. 2007; 41(3): 347-351. ISSN: 0325-2957.
Henry RJ, Chiamori SL, Segalove JM. Determination of Ceruloplasmin Oxidase in Serum. Exp Biol Med. (Maywood) 1960; 104 (4): 300-312.
Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson’s disease: an experience over three decades. Gut. 2000; 46(3): 415-419. DOI: 10.1136/gut.46.3.415.
Schosinsky KH, Lehmann P, Beeler M. Measurement of Ceruloplasmin from Its Oxidase Activity in Serum by Use of o-Dianisidine Dihydrochloride. Clinical Chemistry. 1974; 20(12): 1556-1563. PMID: 4214636.
Carpio Meléndez P. Estudio de la Ceruloplasmina en sujetos de nuestro medio. An Fac med. 1968; 51(2): 56-67. ISSN: 1025-5583.
Ravin M, Herbert A. An improved colorimetric enzymatic assay of ceruloplasmin. The Journal of laboratory and clinical medicine. 1961; 58: 161-168. PMID: 13739892.
Walshe J M, et al. Wilson’s disease: the importance of measuring serum ceruloplasmin non-immunologically. Annals of clinical biochemistry. 2003; 40(2): 115-121. DOI: 10.1258/000456303763046021.
